Evidence map›Paper›PMID 36876464›Full record

ArticleDrug delivery2023

Design and evaluation of

Vishwa J Kalaria, S Saisivam, Anas Alshishani, Jameel S Aljariri Alhesan, Sumit Chakraborty, Mohamed Rahamathulla

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Design and PreliminaryCurrent pharmaceutical biotechnology · 2026
    Article
  3. Article
  4. Article
  5. Factors affecting onJournal of advanced pharmaceutical technology & research
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Vishwa J KalariaN. R. Vekaria Institute of Pharmacy affiliated to Gujarat Technological University, Junagadh, Gujarat, India.
S SaisivamN. R. Vekaria Institute of Pharmacy affiliated to Gujarat Technological University, Junagadh, Gujarat, India.
Anas AlshishaniFaculty of Pharmacy, Zarqa University, Zarqa, Jordan.
Jameel S Aljariri AlhesanFaculty of Pharmacy, Zarqa University, Zarqa, Jordan.
Sumit ChakrabortyN. R. Vekaria Institute of Pharmacy affiliated to Gujarat Technological University, Junagadh, Gujarat, India.
Mohamed RahamathullaDepartment of Pharmaceutics, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Traditional eye drops used for topically administering drugs have poor ocular bioavailability due to the biological barriers of the eye. There is an interest to design and develop novel drug delivery systems that would extend the precorneal residence time, reduce the frequency of administration and decrease dose-related toxicity. This study aimed to prepare Nanoparticles of Gemifloxacin Mesylate and incorporate them into an

Indexed as

ChitosanNanoparticlesAnti-Bacterial AgentsGemifloxacinGram-Negative BacteriaGram-Positive BacteriaOphthalmic SolutionsAnti-Bacterial AgentsChitosanGemifloxacinOphthalmic Solutions32 factorial designantimicrobial activityChitosanin situ gelnanoparticlesOcular drug deliveryPoloxamer 407

Identifiers

PMID36876464
PMCPMC10191058

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.